Standout Papers

Endometrial cancer 2005 2026 2012 2019 1.1k
  1. Endometrial cancer (2005)
    Frédéric Amant, Philippe Moerman et al. The Lancet
  2. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy (2017)
    George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology
  3. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019)
    George W. Sledge, Masakazu Toi et al. JAMA Oncology
  4. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer (2021)
    Ayse Bassez, Hanne Vos et al. Nature Medicine
  5. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 (2014)
    Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology
  6. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (2021)
    Hope S. Rugo, Florence Lerebours et al. The Lancet Oncology
  7. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021)
    Dennis J. Slamon, Patrick Neven et al. Annals of Oncology

Immediate Impact

7 by Nobel laureates 5 from Science/Nature 132 standout
Sub-graph 1 of 17

Citing Papers

Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer
2024 Standout
A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer
2023 Standout
16 intermediate papers

Works of Patrick Neven being referenced

A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
2021 Standout
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
2008
and 6 more

Author Peers

Author Last Decade Papers Cites
Patrick Neven 8402 4816 4330 486 15.2k
Gini F. Fleming 7997 2607 3646 326 16.2k
Roger A’Hern 8368 4903 4373 279 18.6k
Hyman B. Muss 16825 5544 9175 550 29.0k
W. Jonat 4579 1693 3592 292 9.5k
Ursula A. Matulonis 13055 2405 3036 424 22.4k
Beth Y. Karlan 6294 1599 3799 328 18.4k
Isabelle Ray‐Coquard 6720 4876 1700 390 15.4k
Frédéric Amant 6917 3159 3092 530 21.0k
R. Kreienberg 4223 1315 3351 428 10.4k
Martee L. Hensley 4081 4631 1085 220 12.9k

All Works

Loading papers...

Rankless by CCL
2026